Table 1.
Summary of SMR data mining across NDDs
| Disease | Total genes (unique) | Liver genes | Total eQTL genes (non-multi-ancestry) | Replicated in multi-Ancestry | Total druggable genes | % Druggable | Total non-druggable genes | % Non-druggable |
|---|---|---|---|---|---|---|---|---|
| All tested genes (protein coding) | ||||||||
| AD | 16,833 | 1,597 | 15,112 | 8,404 | 3,562 | 21.2% | 13,271 | 78.8% |
| ALS | 16,875 | 1,610 | 15,163 | 8,408 | 3,565 | 21.1% | 13,310 | 78.9% |
| FTLD | 16,788 | 1,537 | 15,038 | 8,394 | 3,551 | 21.2% | 13,237 | 78.8% |
| LBD | 16,797 | 1,540 | 15,069 | 8,388 | 3,554 | 21.2% | 13,243 | 78.8% |
| PD | 16,872 | 1,596 | 15,159 | 8,407 | 3,566 | 21.1% | 13,306 | 78.9% |
| PSP | 16,042 | 1,033 | 13,839 | 8,073 | 3,420 | 21.3% | 12,622 | 78.7% |
| Significance p_SMR_multi< 0.05 andp_HEIDI> 0.01 | ||||||||
| AD | 8 | 175 | 3,189 | 2,079 | 1,142 | 14,275.0% | 3,806 | 47,575.0% |
| ALS | 3,188 | 83 | 1,857 | 1,260 | 715 | 22.4% | 2,473 | 77.6% |
| FTLD | 2,318 | 78 | 1,243 | 810 | 542 | 23.4% | 1,776 | 76.6% |
| LBD | 2,530 | 82 | 1,384 | 900 | 580 | 22.9% | 1,950 | 77.1% |
| PD | 3,592 | 108 | 2,161 | 1,434 | 811 | 22.6% | 2,781 | 77.4% |
| PSP | 2,275 | 30 | 1,270 | 842 | 574 | 25.2% | 1,701 | 74.8% |
| Significance p_SMR_multi< 2.95E-06 (testing all protein coding genes) and p_HEIDI> 0.01 | ||||||||
| AD | 116 | 2 | 68 | 7 | 31 | 26.7% | 85 | 73.3% |
| ALS | 3 | 0 | 3 | 0 | 0 | 0.0% | 3 | 100.0% |
| FTLD | 0 | 0 | 0 | 0 | 0 | 0.0% | 0 | 0.0% |
| LBD | 5 | 0 | 1 | 0 | 1 | 20.0% | 4 | 80.0% |
| PD | 46 | 3 | 33 | 5 | 15 | 32.6% | 31 | 67.4% |
| PSP | 9 | 0 | 5 | 3 | 2 | 22.2% | 7 | 77.8% |
| Significance p_SMR_multi< 1.58E-08 (testing all protein coding genes across all omics) & p_HEIDI> 0.01 | ||||||||
| AD | 47 | 1 | 19 | 19 | 14 | 29.8% | 33 | 70.2% |
| ALS | 1 | 0 | 0 | 0 | 0 | 0.0% | 1 | 100.0% |
| FTLD | 0 | 0 | 0 | 0 | 0 | 0.0% | 0 | 0.0% |
| LBD | 2 | 0 | 0 | 0 | 1 | 50.0% | 1 | 50.0% |
| PD | 24 | 1 | 14 | 14 | 8 | 33.3% | 16 | 66.7% |
| PSP | 8 | 0 | 5 | 5 | 2 | 25.0% | 6 | 75.0% |
AD, Alzheimer disease; ALS, amyotrophic lateral sclerosis; FTLD, frontotemporal dementia lobar degeneration; LBD, Lewy body dementia; PD, Parkinson disease; PSP, progressive supranuclear palsy.